Robert W. Baird Boosts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $62.00

Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target boosted by Robert W. Baird from $52.00 to $62.00 in a research note issued to investors on Thursday, Benzinga reports. They currently have an outperform rating on the stock. A number of other equities research analysts have also recently commented on CRNX. Oppenheimer raised their […]

Related Keywords

Texas ,United States ,Arizona ,Stephenf Betz ,Piper Sandler ,Richard Scott Struthers ,Robertw Baird ,News Ratings For Crinetics Pharmaceuticals Daily ,Victory Capital Management Inc ,Analyst Recommendations For Crinetics Pharmaceuticals ,Securities Exchange Commission ,Crinetics Pharmaceuticals Stock Performance ,Principal Financial Group Inc ,Crinetics Pharmaceuticals Inc ,Crinetics Pharmaceuticals ,Mirae Asset Global Investments Co ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,Scott Struthers ,Asset Global Investments ,Retirement System ,Financial Group ,Capital Management ,Arizona State Retirement System ,State Retirement System ,Crinetics Pharmaceuticals Daily ,